Seagen Inc.


SKU: SGEN Category:


Seagen is currently in advanced talks to be acquired by pharma major, Merck & Co. The company had a strong start to 2022 with first-quarter revenues of $426 million, including net product sales of $383 million, up 27% from the same period the previous year. These were fueled by the rapid expansion of Padcev, Tukysa, and Adcetris. Additionally, compared to the first quarter of 2021, royalties earned in the first quarter of 2022 increased marginally to $28 million. A Phase III Children’s Oncology Group study also showed an improvement in the event-free survival of high-risk young patients with Hodgkin lymphoma. The management intends to keep advancing its deep and diverse pipeline, enhancing its four commercial products and extending its geographic reach. With a cash position of about $2 billion and no debt, they are well-positioned to use cutting-edge innovation to improve the lives of people with cancer today and in the future. Seagen does appear to be an attractive proposition for Merck given its portfolio and pipeline.

Our Report Structure:

⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures

Want unlimited access to our reports? Purchase our $99 annual subscription!